Date: 2014-09-11
Type of information: Grant
Company: Mimetas (The Netherlands)
Investors:
Amount: $1.6 million
Funding type: grant
Planned used: Mimetas will collaborate in a consortium with Radboudumc (Nijmegen, The Netherlands) and FHNW (Basel, Switzerland). The consortium will use the funds to develop, analyze and validate a high-throughput kidney-on-a-chip model by combining Mimetas’ OrganoPlate™ 3D-culturing technology with the human renal cell line ciPTEC™. The resulting model will be used to detect renal tubular injury observed in drug-induced nephrotoxicity. The model’s early prediction of nephrotoxicity will help to reduce animal experiments.
Others: * On September 11, 2014, the organ-on-a-chip company Mimetas has received $1.6 million funding for development of a kidney-on-a-chip for toxicological applications. A panel of experts from GlaxoSmithKline, Pfizer, Roche, NC3Rs and renowned academic institutions has selected MIMETAS’ solution from a strong line-up of competing technologies.
The funding is awarded in the context of the NephroTube CRACK IT Challenge to support development of a microfluidic renal model, predicting renal toxicity during pre-clinical development. The CRACK IT Challenge is organised by the UK-based National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs). In December 2013, Mimetas and her partners received 160.000 dollar funding to develop a successful proof-of-concept.
Therapeutic area:
